{"id":"NCT02224573","sponsor":"GW Research Ltd","briefTitle":"An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes","officialTitle":"An Open Label Extension Study to Investigate the Safety of Cannabidiol (GWP42003-P; CBD) in Children and Adults With Inadequately Controlled Dravet or Lennox-Gastaut Syndromes.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-06-11","primaryCompletion":"2020-09-24","completion":"2020-09-24","firstPosted":"2014-08-25","resultsPosted":"2022-02-03","lastUpdate":"2022-02-03"},"enrollment":681,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy","Dravet Syndrome","Lennox-Gastaut Syndrome"],"interventions":[{"type":"DRUG","name":"GWP42003-P","otherNames":["Cannabidiol","CBD","Epidiolex/Epidyolex®"]}],"arms":[{"label":"GWP42003-P","type":"EXPERIMENTAL"}],"summary":"To investigate the potential antiepileptic effects of cannabidiol (GWP42003-P) in children and adults with Dravet or Lennox-Gastaut syndromes.","primaryOutcome":{"measure":"Number of Participants With Any Treatment-emergent Adverse Event (TEAE) Occurring in ≥5% of Participants in Any Treatment Group","timeFrame":"up to Week 260","effectByArm":[{"arm":"Dravet Syndrome","deltaMin":306,"sd":null},{"arm":"Lennox-Gastaut Syndrome","deltaMin":353,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["34406656","34287833"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":133,"n":315},"commonTop":["Diarrhoea","Pyrexia","Somnolence","Decreased appetite","Convulsion"]}}